Objective: To evaluate the status of lupus nephritis treatment particularly regarding the need for intensification of treatment in Japan from 2010 to 2019 using a large-scale claims database.
Methods: This descriptive study included adult lupus nephritis patients who were administered glucocorticoid equivalent to ≥15 mg prednisolone as the initial dose. After summarizing patient characteristics, we assessed the rate of treatment intensification using the Kaplan-Meier method among six groups based on initial dose of glucocorticoid.
Results: We identified 403 patients (mean age, 42.7 years; 68.5% women) with the median initial glucocorticoid dose of 30 mg/day prednisolone equivalent. We observed 56 treatment intensifications; the incidence rate was 71.3 per 1,000 person-years (95% confidence interval: 52.6-90.0). The rate in higher glucocorticoid dose groups was higher than that in lower glucocorticoid dose groups.
Conclusions: We found that the rate of treatment intensification was higher in the high-dose glucocorticoid groups than in the low-dose glucocorticoid groups. Further studies are needed to clarify the relationship between the initial dose of glucocorticoids and the prognosis of lupus nephritis patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/03007995.2023.2281498 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Macrophage Infiltration Correlated with IFI16, EGR1 and MX1 Expression in Renal Tubular Epithelial Cells Within Lupus Nephritis-Associated Tubulointerstitial Injury via Bioinformatics Analysis.
J Inflamm Res
December 2024
Department of Nephrology, Blood Purification Research Center, the First Affiliated Hospital, Fujian Medical University, Fuzhou, People's Republic of China.
Objective: A comprehensive bioinformatics analysis was conducted to investigate potential new diagnostic biomarkers and immune infiltration characteristics associated with tubulointerstitial injury in lupus nephritis (LN), and to examine possible correlations between key genes and infiltrating immune cells.
Methods: The GSE32591, GSE113342, and GSE200306 datasets were downloaded from the Gene Expression Omnibus database and differentially expressed genes (DEGs) were identified in the pooled dataset. Support vector machine-recursive feature elimination analysis and the least absolute shrinkage and selection operator regression model were used to screen for possible markers, and the compositional patterns of the 22 types of immune cell fractions in LN were determined using CIBERSORT.
Hyperlipidemia in Saudi Arabian Patients With Systemic Lupus Erythematosus.
Cureus
November 2024
Rheumatology, King Saud Medical City, Riyadh, SAU.
Background Systemic lupus erythematosus (SLE) is a chronic autoimmune disease associated with increased cardiovascular risk, partly due to dyslipidemia. This study aimed to evaluate the lipid profiles of Saudi Arabian patients with SLE and examine the impact of hydroxychloroquine (HCQ) and steroid use on these profiles, with a particular focus on patients with lupus nephritis. Methods A retrospective observational study was conducted at King Saud Medical City, Riyadh, Saudi Arabia, including SLE patients treated at the hospital's rheumatology clinic between July 2023 and December 2023.
View Article and Find Full Text PDFMulti-stain deep learning prediction model of treatment response in lupus nephritis based on renal histopathology.
Kidney Int
December 2024
Department of Pediatrics, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China. Electronic address:
The response of the kidney after induction treatment is one of the determinants of prognosis in lupus nephritis, but effective predictive tools are lacking. Here, we sought to apply deep learning approaches on kidney biopsies for treatment response prediction in lupus nephritis. Patients who received cyclophosphamide or mycophenolate mofetil as induction treatment were included and the primary outcome was 12-month treatment response, complete response defined as 24h urinary protein under 0.
View Article and Find Full Text PDFSystemic lupus erythematosus-specific CD14IFITM3 monocyte: Implications for disease activity and progression.
Int Immunopharmacol
December 2024
Department of Rheumatology and Immunology, Weifang People's Hospital, Shandong Second Medical University, Weifang 261000, Shandong, China; Medical Research Center, Weifang People's Hospital, Shandong Second Medical University, Weifang 261000, Shandong, China. Electronic address:
Interferon-inducible transmembrane (IFITM) family members (IFITM1, IFITM2, IFITM3) are extensively expressed in T cells and are involved in adaptive immunity. However, little is known about the expression of IFITM1, IFITM2 and IFITM3 in monocytes and their roles in systemic lupus erythematosus (SLE). Our study has shown that the expression of IFITM1, IFITM2, and IFITM3 in peripheral blood mononuclear cells (PBMCs) of SLE patients was dysregulated, and the expression of IFITM3 in SLE was significantly higher than that of healthy controls.
View Article and Find Full Text PDFExploring potential multiple molecular biomarkers that predict treatment response in patients with lupus nephritis.
Sci Rep
December 2024
Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, 222-1 Wangsimni-ro, Seongdong-Gu, Seoul, 04763, Korea.
Limited knowledge exists regarding biomarkers that predict treatment response in Lupus nephritis (LN). We aimed to identify potential molecular biomarkers to predict treatment response in patients with LN. We enrolled 66 patients with active LN who underwent renal biopsy upon enrollment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!